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Abstract
The p75 neurotrophin receptor (p75NTR) is expressed by neurons particularly vulnerable in Alzheimer’s disease (AD). We tested
the hypothesis that non-peptide, small molecule p75NTR ligands found to promote survival signaling might prevent Ab-
induced degeneration and synaptic dysfunction. These ligands inhibited Ab-induced neuritic dystrophy, death of cultured
neurons and Ab-induced death of pyramidal neurons in hippocampal slice cultures. Moreover, ligands inhibited Ab-induced
activation of molecules involved in AD pathology including calpain/cdk5, GSK3b and c-Jun, and tau phosphorylation, and
prevented Ab-induced inactivation of AKT and CREB. Finally, a p75NTR ligand blocked Ab-induced hippocampal LTP
impairment. These studies support an extensive intersection between p75NTR signaling and Ab pathogenic mechanisms, and
introduce a class of specific small molecule ligands with the unique ability to block multiple fundamental AD-related signaling
pathways, reverse synaptic impairment and inhibit Ab-induced neuronal dystrophy and death.
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Introduction
Slowing the progression of Alzheimer’s disease (AD) will likely
require parallel strategies of managing amyloid-beta (Ab) levels
and reducing neuronal vulnerability to Ab. With regard to
neuroprotective strategies, the p75 neurotrophin receptor
(p75NTR) is an attractive target [1,2]. Binding of neurotrophins,
including nerve growth factor (NGF), to p75NTR promotes pro-
apoptotic or pro-survival signaling, depending on the recruitment
of survival- versus death-promoting adaptors [3,4]. p75NTR is
expressed in adult brain primarily by basal forebrain cholinergic
neurons, but also by hippocampal, entorhinal and neocortical
neurons, each vulnerable in AD (reviewed in [5]). Moreover,
p75NTR expression is upregulated in cortical [6] and hippocampal
[7] tissue in AD. Increased p75NTR and decreased Trk
neurotrophin receptor levels in AD, along with studies showing
that increased p75NTR/Trk ratios lead to neuronal degeneration,
further encourage therapeutic targeting of p75NTR [4].
Substantial overlaps exist between p75NTR-mediated signaling and
degenerative signaling in AD. In AD brain and in cultured neurons
treated with Ab, there is excessive activation of calpain/cdk5 [8],
GSK-3b [9], and JNK and its downstream transcriptional activator c-
Jun [10]. p75NTR stimulates calpain activation through its Chopper
cell death domain, [11] and mediates NGF-induced inhibition of
GSK-3b [12]; in addition, it can mediate induction of cell death
through the activation of JNK [13]. Further, it has been reported that
Ab can bind to p75NTR, and the receptor mediates Ab-induced cell
death, in part by induction of c-Jun activation [1,14,15]. Thus, there
are numerous potential points of direct and indirect interactions
between p75NTR and AD pathogenic mechanisms.
p75NTR represents a significant target for AD therapeutic
development from a number of perspectives. To the extent that
direct interactions between p75NTR and Ab contribute to AD,
preventing those interactions could inhibit neurodegeneration.
Further, modulating the receptor to reduce activation of c-Jun and
calpain activity could counteract Ab activation of these signaling
intermediates. Moreover, since Ab down-regulates trophic signaling,
particularly the PI3K/AKT pathway which promotes survival and is
important for synaptic function [16], the promotion of AKT
activation by ligand binding to p75NTR [3,17] may reduce the effects
of Ab In addition, AKT down-regulates JNK [18] and GSK3b [19].
Thus, targeting p75NTR could protect neurons from Ab by at least
three possible mechanisms: i) blocking a deleterious interaction
between Ab and p75NTR; ii) down-regulating deleterious signaling
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(calpain, GSK3b and c-Jun) which mediates Ab toxicity; iii)
upregulating survival signaling (AKT) which is normally inhibited
by Ab and which can antagonize Ab mechanisms. The latter two
mechanisms could be operative even under circumstances in which
Ab causes degeneration independent of p75NTR.
Aberrant activation of the cdk5, GSK3b and JNK kinases leads
to tau hyperphosphorylation, cytoskeletal disruption and neuritic
dystrophy [20]. Also, excessive activation of these kinases along
with Ab-induced inhibition of CREB activation causes synaptic
dysfunction [21–23]. Thus, small molecules inhibiting activation of
cdk5, GSK3b, JNK and/or c-Jun have become important
therapeutic candidates [20,24,25]. However, it seems unlikely
that modulating a single target will provide an effective therapy; in
addition, given the ubiquity of these targets and their functions in a
very broad range of cell types it may be anticipated that adverse
effects will limit their utility. Therefore, the possibility of inhibiting
Ab-induced excessive activation of cdk5, GSK3b and c-Jun
through a receptor expressed by neurons particularly vulnerable in
AD is an attractive strategy for therapeutic development.
Expanding on development of synthetic peptides modeled on
loop 1 of NGF that prevent neuronal death through p75NTR-
mediated mechanisms [26], we identified small molecule, non-
peptide ligands, with favorable pharmaceutical properties, that bind
specifically to p75NTR and activate survival-promoting signaling,
including AKT, in hippocampal neurons ([17], reviewed in [5]). In
the present study, we tested the hypothesis that these ligands would
interfere with deleterious Ab signalling and its functional conse-
quences. We demonstrate that these compounds inhibit Ab-induced
neuronal death, neuritic degeneration and activation of calpain/
cdk5, GSK3b, and c-Jun; and reverse Ab-mediated inhibition of
AKT and CREB activation, and synaptic function. These findings
suggest that the use of small molecule p75NTR ligands may be a
therapeutically feasible approach to AD capable of simultaneously
targeting multiple underlying pathogenic mechanisms.
Results
p75NTR small molecule ligands inhibit Ab-induced death
of hippocampal, cortical and septal neurons
Ligands LM11A-24 and LM11A-31 were selected from p75NTR
ligands developed by our laboratories based on chemical and
pharmacological features favorable for drug development [17].
LM11A-31 is an isoleucine derivative (MW 243.3) and LM11A-24
is a caffeine derivative (MW 322.4). LM11A-36 is structurally similar
to LM11A-24 but is inactive in neurotrophic assays [17] and served as
a negative control (Fig. S1). 6–7 DIV hippocampal, cortical and
septal neurons were treated with oligomeric Ab in the presence or
absence of p75NTR small molecule ligands or NGF. Preliminary
experiments demonstrated that oligomeric Ab (derived from each of
three oligomeric Ab protocols as described inMethods and Fig. S2)
reached maximum toxicity (neuronal death) at 5–10 mM (data not
shown), a concentration range similar to that reported by other
laboratories. Exposure of neurons to Ab resulted in somal shrinkage
and vacuolation along with neurite fragmentation and beading;
whereas the majority of neurons co-treated with Ab and 100 nM
LM11A-24 or LM11A-31 exhibited a normal appearance with intact
cell bodies and neurites (Fig. 1A–D). Quantitative analysis of
hippocampal, cortical, and septal neuronal cultures demonstrated
that Ab induced a 40–65% reduction in survival while simultaneous
addition of LM11A-24 or LM11A-31 prevented 70–90% of the Ab-
induced decrease in survival. NGF and LM11A-36 had no protective
effect except for a minor protective effect by NGF in hippocampal
and septal cultures (Fig. 1E, G). In dose-response studies, LM11A-
24 and -31 inhibited Ab-induced death with EC50 values of,20 nM,
with the protective effect persisting to at least 500 nM (Fig. 1H, I).
LM11A-31 was also found to be protective against Ab fibrillar
preparations (Fig. 1J).
To confirm that p75NTR ligands prevent Ab-induced neuronal
death, hippocampal neuronal survival was further assessed using
Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End
Labeling (TUNEL)/DAPI staining. Neurons treated with Ab
exhibited increased TUNEL staining whereas fewer neurons co-
treated with Ab and LM11A-31 demonstrated TUNEL signal
(Fig. 2A–C). Quantitative analyses (Fig. 2D) demonstrated that in
the absence of Ab, addition of LM11A-31 had no significant effect
on neuronal survival while NGF was associated with a small but
statistically significant increase in death. These findings were
consistent with previous studies showing that under certain culture
conditions, NGF promotes death of hippocampal neurons [27].
LM11A-31 inhibited Ab-induced death while NGF had no
protective effect. The ability of LM11A-31 and LM11A-24 to
block Ab-induced death was further confirmed using Hoechst
staining (Fig. S3).
Small molecule ligand protection is mediated through
p75NTR
Previous studies [17] demonstrated specificity of LM11A-24 and
-31 for p75NTR. The ability of p75NTR ligands to induce PI3K/
AKT activation was entirely dependent on p75NTR and these
ligands did not activate Trk receptors [17]. These previous studies
also demonstrated differential activities of neurotrophins and the
small molecule ligands on p75NTR-expressing cells. In cultures of
oligodendrocytes, which express p75NTR but not Trk receptors,
NGF or proNGF can induce cell death; however, LM11A-24 and
-31 not only failed to promote death but blocked neurotrophin-
induced death. In the current study, we reasoned that if a
compound promotes its protective effect through a ligand-type
interaction with p75NTR, this effect should be blocked by the
addition of a receptor-saturating concentration of a competing,
non-protective ligand, such as NGF. The addition of NGF
(100 ng/ml) together with LM11A-31 (100 nM) reversed entirely
the protective effect of LM11A-31 (Fig. 2D), consistent with a
model in which these compounds act through a common receptor.
An alternative explanation is that toxicity induced by NGF might
mask a non- p75NTR-dependent protective mechanism of LM11A-
31. As a second approach for determining whether the LM11A-31
protective effect was mediated through p75NTR, assays were
conducted using p75NTR+/+ and p75NTR2/2 hippocampal
neurons derived from mice maintained on a C57Bl/6-strain
background. Using neurons from that strain, maximum Ab-
induced death was reached at 2.5 mM Ab and this dose was
therefore used for subsequent studies. In p75NTR+/+ cultures, Ab
triggered a 2-fold increase in death that was significantly inhibited
by LM11A-31, a protective effect consistent with earlier studies
(Fig. 2E). In p75NTR2/2 cultures, significant Ab toxicity was
reduced to a 1.5-fold increase in death. The significant difference
in the degree of cell death triggered in p75NTR wildtype and
mutant cultures indicated that the presence of wildtype p75NTR
contributes to Ab-induced toxicity. Notably, in p75NTR2/2
cultures LM11A-31 had no protective effect, indicating a
protective mechanism requiring p75NTR.
p75NTR small molecule ligands prevent Ab-induced
neuronal death in organotypic hippocampal slice
cultures
Organotypic slice culture derived from postnatal brain and
matured in vitro, is a widely used model for the study of
p75NTR Ligands in AD Models
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Figure 1. p75NTR small molecule ligands protect neurons from Ab-induced death. 6–7 DIV hippocampal, cortical and septal neurons were
exposed to: culture medium alone (CM); CM containing 10 mM Ab(S), a control peptide containing Ab(1-42) residues in a scrambled sequence; 10 mM
Ab alone or with NGF (100 ng/ml , ,4 nM), LM11A-24, -31, or -36 (100 nM). After 72 hours, cultures were fixed and photographed under phase
contrast microscopy. (A) In CM alone, neurons had round, phase bright cell bodies with outgrowth of intact neurites (normal morphology). (B) In the
presence of Ab, many neurons exhibited the degenerative findings of cell body shrinkage (arrowheads), vacuolated cytoplasm, and neurite beading
and fragmentation (arrows). (C, D) Neurons co-treated with Ab and LM11A-24 (C) or LM11A-31 (D) exhibited normal morphology. (E–J) Neuronal
survival was quantitated using morphological criteria (see Methods) and survival in each experimental condition was statistically compared to Ab
alone. In cultures of hippocampal (E) cortical (F) and septal (G) neurons, Ab significantly decreased survival while Ab (S) had no effect. LM11A-24 and
-31 inhibited Ab-induced death while NGF and LM11A-36 negative control compound demonstrated no protective effects with the exception of NGF
exhibiting a small protective effect in hippocampal and septal cultures (for hippocampal cultures, n = 45–146 fields counted over 5–16 separate
experiments; for cortical cultures, n = 25–40 fields counted over 5 separate experiments; for septal cultures, n = 50–60 fields counted over 6 separate
experiments). (H, I) 6–7 DIV hippocampal neurons were exposed to CM alone or Ab in the presence or absence of LM11A-24 (H) or -31 (I) at the
p75NTR Ligands in AD Models
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neurodegenerative mechanisms and potential therapeutics. Addi-
tion of Ab to rat postnatal hippocampal slice cultures leads to
death of pyramidal neurons as detected by propidium iodide (PI)
uptake [28]. In our studies, 24 hour Ab exposure led to markedly
increased in PI staining by pyramidal neurons which was blocked
entirely by co-treatment with LM11A-31 (Fig. 3).
Figure 2. LM11A-31 inhibition of Ab-induced toxicity is p75NTR
dependent. (A–C) 6–7 DIV hippocampal neurons were treated with:
(A) CM alone; (B) 5 mM Ab; (C) 5 mM Ab+100 nM LM11A-31 for
72 hours and then stained with TUNEL/DAPI. Many neurons exposed to
Ab were TUNEL-positive (green), indicative of death; whereas the
majority of neurons co-treated with Ab and LM11A-31 were TUNEL-
negative. (D) Quantitation of the percentage of TUNEL-positive neurons
demonstrated that LM11A-31 alone had no effect on baseline death
while NGF (100 ng/ml) was associated with a significant increase in
death. Ab caused an approximate 2.0-fold increase in death that was
significantly inhibited by LM11A-31 but not NGF. In the presence of
NGF, LM11A-31 failed to prevent Ab-induced death (n = 98–131 fields
derived from a total of 6 separate experiments). (E) In 6–7 DIV
hippocampal neuronal cultures derived fromC57Bl/6 p75NTR+/+ and2/2
mice, Ab triggered a 2.0-fold increase in death in p75NTR+/+ cultures that
was significantly inhibited by LM11A-31. In p75NTR2/2 cultures, Ab
triggered a significant 1.5-fold increase in death, a degree of increase
significantly less than that found in +/+ cultures. In p75NTR2/2 cultures,
LM11A-31 demonstrated no protective effect (n=69–140 fields per
condition, derived from a total of 4 separate p75NTR2/2 cultures and 6
separate p75NTR+/+ cultures).
doi:10.1371/journal.pone.0003604.g002
indicated concentrations. LM11A-24 and -31 were protective against Ab in a dose-dependent manner, with an EC50 of approximately 20 nM (LM11A-
24: n = 20–146 fields counted over 3–16 separate experiments. LM11A-31: n = 43–146 fields counted over 5–16 separate experiments). (J) 6–7 DIV
hippocampal neurons were exposed to CM alone or 10 mM fibrillar Ab6LM11A-31. LM11A-31 inhibited fibril-induced neuronal death (n = 30 fields
counted over 3 separate experiments).
doi:10.1371/journal.pone.0003604.g001
Figure 3. LM11A-31 inhibits Ab-induced death of hippocampal
neurons in postnatal organotypic slice cultures. Organotypic
slice cultures were prepared from PND-8 rat brain and allowed to
mature in vitro for 11–19 days. Pyramidal neuron death was detected
by propidium iodide (PI) staining, and all experimental conditions were
compared to Ab treatment alone. Upper row, at baseline only trace
levels of PI staining were detected. Middle row, PI staining after a
24 hour exposure to either culture medium (CM), Ab or Ab+LM11A-31
at 100 nM demonstrates readily apparent Ab-induced pyramidal
neuron death that is inhibited in the presence of p75NTR ligand.
Bottom row, PI staining shows maximum neuronal death after
24 hour treatment with NMDA. In the lower panel, quantitative analysis
of PI staining demonstrates a significant reduction in Ab-induced
neuronal death (n = 56–59 brain slices derived from 4 independent
studies).
doi:10.1371/journal.pone.0003604.g003
p75NTR Ligands in AD Models
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p75NTR small molecule ligands prevent Ab-induced
neuritic dystrophy in matured neurons
Ab-induced tau/cytoskeletal derangement causes neuritic
dystrophy, a process which occurs in early stages of AD [29]
and is characterized by the appearance of varicosities and
excessive tortuosity [30,31]. Hippocampal neurons kept in vitro
for $3 weeks express mature isoforms of tau protein, and when
exposed to Ab primarily demonstrate neuritic dystrophy rather
than death [30]. Treatment of DIV 21–22 hippocampal neurons
with 5 mM Ab induced dystrophic changes which were prevented
almost entirely by LM11A-24 and -31 (Fig. 4A–D). Assessment of
dystrophy by visual criteria (Fig. 4D) and by quantitation of the
neurite mean differential curvature, a measure of tortuosity
(Fig. 4E–H), showed that these ligands effectively blocked Ab-
induced dystrophy. This finding suggests that the compounds may
interfere at an early/upstream stage with the complex cascade of
Ab-induced signaling [20] which results in the disruption of
neuritic integrity.
p75NTR small molecule ligands prevent Ab-induced AKT
inactivation and their protective effect is dependent, in
part, on PI3K activity
In previous studies with hippocampal neurons, LM11A-24 and -
31 were found to activate AKT in a p75NTR-dependent manner and
their neurotrophic effect was dependent upon PI3K [17]. These
findings raised the possibility that these ligands might counteract the
ability of Ab to decrease levels of AKT activation. Treatment of 21–
22 DIV hippocampal neurons with Ab induced a significant
decrease in AKT activity that was blocked by LM11A-24, -31 and
NGF, although the effect of NGF was less than that of the small
molecules (Fig. 5A). To determine whether the small molecule
protective effect was dependent upon PI3K/AKT activity, we co-
treated 6–7 DIV hippocampal neurons with Ab, LM11A-24 or -31,
and LY294002, an inhibitor of PI3K. Under baseline conditions
(Fig. 5B), LY294002 induced a 1.7-fold increase in cell death
without reaching significance, a trend consistent with the known
role of PI3K/AKT signaling in promoting neuronal survival [3]. In
the presence of Ab without LY294002, LM11A-24 and -31 blocked
the Ab-death promoting effect consistent with earlier results.
However, in the presence of LY294002, the protective effect of
LM11A-24 and -31 was significantly reduced. The ability of
LY294002 to block the p75NTR ligand protective effect, along with
the finding that p75NTR ligands reverse Ab-induced inhibition of
AKT activation, suggest that maintenance of PI3K/AKT signaling
by LM11A-24 and -31 contributes to their protective effect.
p75NTR small molecule ligands inhibit Ab-induced
activation of calpain/cdk5, GSK3b and c-Jun
Activation of calpain results in the cleavage of the 250 kDa
cytoskeletal protein a-fodrin to 145 and 150 kDa fragments, and
the levels of these fragments serve as a measure of calpain activity
[32]. Exposure of 21–22 DIV hippocampal neurons to Ab
triggered a nearly 3-fold increase in the ratio of fragmented to
full-length a-fodrin forms (Fig. 5C). Of note, a-fodrin is also a
substrate for caspase 3 in degenerative states, with cleavage to
150 kDa and 120 kDa forms [33]. Quantitation of 120 kDa a-
fodrin fragments revealed no significant differences across
conditions (data not shown) suggesting that Ab-induced cleavage
resulted from calpain rather than caspase activity. LM11A-24, -31
and NGF inhibited Ab-induced a-fodrin cleavage, indicating that
they prevented Ab-induced calpain activation.
Activated calpain cleaves the cdk5 p35 regulatory subunit to the
p25 constitutively active form promoting excessive cdk5 activation;
the ratio of p25 to p35 reflects cdk5 activation [32]. Treatment of
21–22 DIV neurons with Ab resulted in markedly increased p35
cleavage, as evidenced by a significant increase in the ratio of p25
to p35 (Fig. 5D). Co-treatment with LM11A-24, -31 or NGF
prevented the increase in p25/p35 ratio, demonstrating that
p75NTR ligands inhibit Ab-induced cdk5 activation.
Given that LM11A-24 and -31 promote PI3K/AKT signaling
[17] and that this signaling inhibits GSK3b [19] and JNK
activation [34], we determined whether these ligands, as well as
NGF, prevent Ab-induced GSK3b and c-Jun activation. GSK3b
activity is increased when the Ser9 residue is dephosphorylated,
providing a measure of the GSK3b activation state [19]. Addition
of Ab to 21–22 DIV cultures induced significant dephosphoryla-
tion (i.e., activation) of GSK3b, while co-administration with
LM11A-24 and -31, but not NGF, prevented this activation
(Fig. 5E). An established method for monitoring JNK and c-Jun
activation consists of quantitating neuronal nuclei positive for
phospho-c-Jun immunostaining [35]. Treatment of 6–7 DIV
neurons with Ab resulted in activation of c-Jun, which was largely
inhibited by co-treatment with LM11A-24 or -31 but not by NGF
(Fig. 5F).
In summary, LM11A-24 and -31, but not NGF, demonstrated
significant inhibition of Ab-induced GSK3b and c-Jun activation.
In contrast, LM11A-24, -31 and NGF each inhibited the ability of
Ab to downregulate AKT signaling and to promote calpain/cdk5
signaling. These differences in signaling profiles between the small
molecules and NGF might account, in part, for the greater
protective effects of the small molecules and point to the
importance of GSK3b and c-Jun activation in mediating Ab-
induced degeneration.
Since cdk5, GSK3b and JNK contribute to Ab-induced tau
phosphorylation [20,24,25], we determined whether LM11A-24
and -31 might also prevent tau phosphorylation. In 21–22 DIV
neurons, exposure to Ab resulted in a significant increase in tau
phosphorylation at Ser202, a well characterized tau residue which
is phosphorylated by each of these kinases and which is found to
be phosphorylated in early AD [25,36,37]. Co-administration of
LM11A-24 or -31 almost entirely prevented Ab-induced tau
Ser202 phosphorylation (Fig. 5G).
p75NTR small molecule ligands prevent Ab-induced
inactivation of CREB
In addition to aberrant activation of calpain/cdk5, GSK3b and
JNK, another potential mechanism by which Ab inhibits synaptic
function is through inhibition of CREB, a fundamental contrib-
utor to long-term potentiation (LTP) [21]. To further examine the
effects of LM11A-24 and -31 on Ab-induced changes in signaling,
we determined whether these ligands were capable of blocking Ab-
induced CREB deactivation. Treatment of 21–22 DIV hippo-
campal neurons with Ab for 3 hours resulted in a 43% reduction
in phosphorylation of CREB, consistent with previous studies [21].
Notably, co-treatment with 100 nM LM11A-24 or -31 blocked the
inhibitory effect of Ab on CREB phosphorylation (Fig. 5H).
LM11A-31 corrects deficits in synaptic transmission in Ab-
treated hippocampal slices
The effect of the ligands on CREB phosphorylation strongly
suggested that they might be able to reverse the Ab-induced
inhibition of LTP in the brain. Electrophysiological experiments
were performed on hippocampal slices derived from adult mice
that received a tetanus to produce LTP at the Shaffer collateral-
CA1 connection. As previously shown [21], we found that the
exposure of slices to Ab (200 nM) for 20 min before tetanization
p75NTR Ligands in AD Models
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Figure 4. p75NTR small molecule ligands prevent Ab-induced neuritic dystrophy. 21–22 DIV hippocampal neurons were exposed to the
following conditions: (A) culture medium (CM); (B) 5 mM oligomeric-NaOH-derived Ab; or (C) 5 mM oligomeric-NaOH-derived Ab+100 nM LM11A-31.
After 48 hours, cultures were fixed and immunostained for MAP2 to visualize dendrites. In the presence of CM alone, dystrophic changes including
beading and tortuosity were rare. In contrast, Ab induced beading (arrowheads) and increased tortuosity (brackets), and each of these changes was
markedly reduced with co-administration of LM11A-31. (D) Dystrophic neurites, defined as neurites exhibiting beading and/or multiple abrupt turns
(i.e., tortuosity) were measured by a blinded observer. Data is expressed as average numbers of dystrophic neurites per field. All conditions were
compared to Ab alone (n = 8 randomly chosen fields from 3 independent experiments). (E) Mean differential curvature (MDC) analysis in randomly
selected fields demonstrated that oligomeric-NaOH-derived Ab induced a significant increase in MDC which was prevented by LM11A-31 (n = 7–9
fields per condition). (F) Distribution analysis of MDC values (X axis) demonstrates a rightward shift in the presence of oligomeric-NaOH-derived Ab
that was mitigated in the presence of LM11A-31. (G–H) The same assays and analyses were performed using 5 mM oligomeric-HFIP-derived Ab which
demonstrated similar findings (n = 9 fields per condition derived from 3 independent experiments).
doi:10.1371/journal.pone.0003604.g004
p75NTR Ligands in AD Models
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Figure 5. Modulation of Ab-induced deleterious signaling. For each study, LM11A-24 and -31 were present at 100 nM and NGF at 50 or
100 ng/ml. All conditions were compared to Ab treatment alone, unless indicated otherwise (e.g. Fig. 5B). For the majority of protein preparations,
each derived from separate experiments; two independent Western analyses were conducted. (A) DIV 21–22 hippocampal neurons were treated with
CM alone, CM+Ab, or Ab in the presence of LM11A-24, -31 or NGF and examined at the 4 hour time point. AKT activation was significantly decreased
by Ab, while LM11A-24, -31 and NGF prevented this decrease. The ability of NGF to prevent Ab-induced AKT inhibition was diminished relative to that
of the small molecules (n = 8–14 separate Western blots from 9 independent protein preparations). (B) Neurons were treated with CM alone or with
the indicated combinations of the PI3K inhibitor LY294002, Ab and LM11A-24 or -31. After 72 hours, cultures were stained with Hoechst 33258 for cell
death quantitation. In CM, LY294002 increased cell death by approximately 1.7-fold without reaching significance. In the presence of Ab, LY294002
blocked the protective effect of p75NTR ligands and resulted in a . 2.0-fold increase in cell death (n = 35–45 fields derived from a total of 4–5
experiments for each condition). (C–E) DIV 21–22 hippocampal neurons were treated with CM or Ab in the presence of LM11A-24, -31 or NGF for
4 hours. (C) Addition of Ab resulted in increased calpain-induced cleavage of full-length a-fodrin (250 kDa) to its 150 and 145 kDa fragments. Co-
treatment with LM11A-24, -31 or NGF, significantly reduced Ab-induced calpain activation (n = 4–7 separate Western blots from 4 independent
protein preparations). (D) Addition of Ab induced cdk5 activity as revealed by the increased ratio of the cleaved (p25) to uncleaved (p35) regulatory
subunit. Activation was inhibited by LM11A-24, -31 or NGF (n = 8–10 separate Western blots from 7 independent protein preparations). (E) Addition
of Ab induced GSK3b activation as revealed by a decrease in the ratio of p-GSK3bSer9 signal to total GSK3b. Activation was significantly inhibited by
LM11A-24 and 31, but not NGF (n = 8–14 separate Western blots from 7 independent protein preparations). (F) In DIV 6–7 neuronal cultures
examined at the 12 hour time point, Ab induced a 1.8-fold increase in the proportion of phospho-c-Jun positive nuclei, a measure of JNK/c-Jun
activation. Activation was significantly inhibited by LM11A-24 and 31, but not NGF (n = 139–210 fields from 6 individual experiments). (G) In DIV 21–
22 hippocampal neuronal cultures examined at the 4 hour time point, Ab induced a 3.5-fold increase in TauSer202 phosphorylation which was
p75NTR Ligands in AD Models
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led to significant impairment of LTP (Fig. 6). However, when
slices were treated concomitantly with Ab and LM11A-31
(100 nM), LTP was normalized. LM11A-31 alone did not affect
potentiation.
Discussion
There is no available therapy for AD that effectively targets
underlying disease mechanisms. The present studies demonstrate
that non-peptide small molecule ligands targeting p75NTR, a
receptor upregulated in neurons vulnerable in AD, prevent Ab-
induced neuritic dystrophy and cell death, while inhibiting Ab-
induced tau phosphorylation and the activation of several key
signaling intermediates, each a candidate therapeutic target in its
own right. The inhibition of Ab-induced and transgenic mouse-
related synaptic impairment, the prevention of neuritic dystrophy
and neuronal death, along with the modulation of multiple
intracellular signaling mechanisms involved in AD is a novel
activity profile for small molecule ligands acting at a known
receptor target.
The protective effect of these compounds is likely mediated
through p75NTR. Their effects on neuronal signaling and survival
are p75NTR-dependent, they induce signaling-adaptor recruitment
to p75NTR and they fail to activate Trk receptors [17]. In addition,
a standardized receptor binding screen conducted with LM11A-31
(Cerep panel, Table S1) failed to detect binding of p75NTR
ligands to other receptors. NGF lacked protective activity, and as
expected for an ‘inactive’ ligand, inhibited the protective effect of
p75NTR small molecule ligands, consistent with their protective
effect being mediated through p75NTR. Moreover, in assays
employing p75NTR2/2 neurons in which Ab-induced death was
reduced but still present to a significant degree, small molecule
ligand protective activity was entirely absent. Taken together, our
prior and current studies indicate that these ligands inhibit Ab-
induced degeneration by interacting with p75NTR. The expression
of p75NTR by glial cells [38] raises the possibility that these ligands
might also function through p75NTR-mediated effects on non-
neurons; however, the relative lack of non-neuronal cells in the
culture protocols applied here and the effects evident in short term
signaling studies make this possibility unlikely.
There are several mechanisms by which p75NTR ligands might
inhibit Ab toxicity. Ab(1-40) aggregates bind to p75NTR and
induce cell death and a modified NGF loop 1 synthetic peptide
was found to block NGF binding to p75NTR and prevent Ab(1-40)-
induced death of cultured cortical neurons [14]. It has yet to be
determined whether Ab(1-42) oligomer species similarly bind to
p75NTR to induce neuronal degeneration. Our finding that Ab(1-
42) oligomer-induced death is significantly, though incompletely,
decreased in p75NTR2/2 cultures suggests that p75NTR might be
one of several targets mediating oligomeric Ab(1-42) effects. Thus,
small molecule p75NTR ligands might prevent degeneration, in
part, by preventing Ab binding to p75NTR. Alternatively, p75NTR
might not be an important target for Ab binding but might instead
contribute to Ab toxic effects through indirect mechanisms. Its
ability to affect deleterious or survival-promoting signaling (i.e. c-
Jun and PI3K/AKT, respectively) might contribute an ‘enabling’
mechanism that augments Ab toxicity. In this scenario, the
protective function of small molecule ligands would be derived
from optimizing the degenerative- versus survival-promoting
functions of p75NTR rather than inhibiting Ab oligomer binding.
The findings that NGF has no protective effect against Ab in some
assays, and that the toxic effect of Ab is only partially lost in
p75NTR2/2 neurons, suggest that the protective effect of p75NTR
small molecule ligands, especially in assays in which toxic effects of
Ab are blocked entirely, is unlikely to be mediated solely by a
simple mechanism of inhibiting Ab binding to p75NTR.
Deleterious functional effects promoted by nanomolar, non-
lethal, concentrations of Ab may occur through mechanisms in
addition to those promoting gross neuronal dystrophy and death.
Recent findings suggest that p75NTR is highly enriched in post-
synaptic densities and interacts with the PDZ3 domain of the PSD-
95 scaffolding protein [39]. In addition, evidence continues to
accumulate that Ab might impair synaptic function by perturbing
PSD-95 related structures and function [40,41]. Thus, the finding
that LM11A-31 is capable of blocking low concentration Ab-
induced impairment of synaptic function in adult hippocampal
slices suggests additional pathways through which p75NTR small
molecule ligands may mitigate Ab effects. LM11A-31 is the first
small molecule ligand shown to prevent Ab-induced synaptic LTP
impairment when administered at nanomolar, rather than
micromolar, concentrations.
The favorable drug development profile of LM11A-24 and -31,
their low nanomolar potency and receptor selectivity, and their
unprecedented ability to simultaneously inhibit Ab-induced
activation of calpain/cdk5, GSK3b and c-Jun and to block Ab
impairment of synaptic function, each of which are current
pharmaceutical candidate targets for AD therapeutics, establish an
important new class of candidate small molecule compounds for
Figure 6. LM11A-31 rescues the deficit in CA1-LTP in Ab-
treated hippocampal slices. Extracellular field excitatory postsynap-
tic potential (fEPSP) was measured as described in Methods. Arrows
indicate tetanus application. The horizontal bar indicates the period
during which Ab and/or LM11A-31 were added to the bath solution. Ab
did not affect baseline transmission. Application of LM11A-31 (100 nM)
rescued Ab-induced impairment of LTP without affecting baseline
transmission. The values for the last data point in the graph are as
follows: vehicle (veh, n = 8) 252.4627.6%; Ab (n = 7) 134.069.3%;
LM11A-31 (n = 7) 230.2624.3%.; Ab+LM11A-31 (n = 7) 233.6617.6%.
Vehicle vs. Ab, p = 0.02; Ab vs. Ab+LM11A-31, p = 0.0006; vehicle vs.
LM11A-31, p = 0.8131.
doi:10.1371/journal.pone.0003604.g006
significantly inhibited by LM11A-24 and -31 (n = 10 separate Western blots from 5 independent protein preparations). (H) In DIV 21–22 hippocampal
neuronal cultures examined at the 3 hour time point, Ab significantly decreased CREB phosphorylation by 43%, while this decrease was prevented by
LM11A-24 and -31 (n = 10 separate Western blots from 5 independent protein preparations).
doi:10.1371/journal.pone.0003604.g005
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AD therapeutics. Novel derivatives of these compounds with
optimized pharmaceutical profiles are currently under study and
will serve as important candidates for clinical development.
Current studies in our laboratories are assessing the ability of
p75NTR ligands to decrease neurite degeneration and to correct
behavioral deficits in transgenic mice that over-express Ab.
Methods
Materials
All chemicals were purchased from Sigma (St Louis, MO),
unless otherwise stated. The PI3-kinase inhibitor LY294002 was
obtained from Calbiochem (La Jolla, CA). Anti-phospho-
GSK3bSer9 polyclonal antibody, anti-phospho-AKT monoclonal
antibody, anti-phospho-CREB polyclonal antibody, anti-mono-
clonal CREB antibody, anti-AKT polyclonal antibody and anti-
phospho-c-Jun polyclonal antibody were purchased from Cell
Signaling (Beverly, MA). Monoclonal anti-GSK3b was obtained
from BIOSOURCE International (Camarillo, CA). Monoclonal
anti-phospho-tauSer202 was purchased from Pierce (Rockford, IL).
Polyclonal anti-tau, monoclonal microtubulin-associated protein-2
(MAP2) and monoclonal anti-actin antibodies were obtained from
Sigma. a-fodrin and p35/p25 antibodies were procured from
Santa Cruz Biotechnology (Santa, Cruz, CA). Mouse submaxillary
NGF was obtained from Invitrogen (San Diego, CA).
Primary neuronal cultures
Animal procedures were approved by each participating
university’s Committee on Laboratory Animal Care and were
conducted in accordance with the NIHGuide for the care and use of
laboratory animals. Cortical, hippocampal and septal cultures were
prepared from embryonic day 16 (E16) CF1 mouse fetuses [42].
Tissue culture wells with or without coverslips were coated with
10 mg/mL poly-L-lysine in PBS. Cells were incubated in DMEM/
F12 containing 10% fetal bovine serum for the first 16-20 hours, and
subsequently maintained in serum-free Neurobasal mediumwith 16
B27 supplement (Invitrogen). p75NTR+/+ or 2/2 hippocampal
neurons were derived from E15-17 mice maintained on a C57Bl/6
background and cultured under the same conditions, with the
addition of 1 mM Glutamax supplement. For neuronal viability
assays, neurons were seeded in 24-well plates at a density of 20,000–
30,000 cells per well or in 12-well plates at 80,000–100,000 cells per
well and allowed to mature 6–7 days. For neuritic dystrophy assays,
150,000–200,000 neurons per well were seeded into 6-well plates
containing 25 mm coverslips and matured 21–22 days. For all
cultures, medium was changed every 48–72 hours, prior to the
addition of Ab and various compounds. MAP2 immunostaining
demonstrated that each of the above protocols resulted in cultures
containing 90–95% neurons with 100% of the MAP2-positive cells
expressing p75NTR. For Western blot signaling assays, the same
protocol was followed except neurons were seeded at 450,000 cells
per well in 6-well plates.
Ab preparations
Ab(1-42), referred to as ‘‘Ab’’, and Ab(S) (Ab(1-42) residues in a
scrambled sequence) were obtained from rPeptide (Athens, GA).
Ab oligomers were prepared using three different established
methods. For the first two, Ab peptide was resuspended in 0.5 mM
NaOH [43] or 0.2% NH4OH [44] at a concentration of 350 mM
and stored at 270uC. For use in cell cultures, the stock solution
was incubated at 37uC for 5–7 days. In the third method [45],
1.0 mg of Ab peptide was dissolved in 250 ml hexafluoroisopro-
panol (HFIP), aliquoted in sterile microcentrifuge tubes and HFIP
was removed under vacuum in a Speed Vac. Resulting peptide
films were stored desiccated at220uC. Before use, the peptide was
resuspended to 5 mM in dry dimethyl sulfoxide (Me2SO, Sigma),
brought to 80 mM in PBS and incubated at 4uC for 16–24 hours.
For the production of Ab fibrils, HFIP-prepared peptide was
brought to 222 mM in 10 mM HCl.
Peptide preparations were characterized by Atomic Force
Microscopy (AFM). A multimode scanning probe microscope
controlled by a NanoScope IIIa controller was used in conjunction
with an E-series piezoelectric scanner (Digital Instruments, Santa
Barbara, CA). AFM probes were etched silicon micro cantilevers,
model MPP-11100 (Veeco, Santa Barbara, CA). Samples were
applied to freshly cleaved mica using a Langmuir-Schaffer
horizontal transfer system, and were then rinsed with Milli-Q
Ultrapure water (Millipore, Temecula, CA) [46]. Image data was
acquired at a scan rate of 0.5–1 Hz. AFM analysis (Fig. S2) of Ab
preparations demonstrated that NaOH- and NH4OH-based
protocols resulted in primarily oligomeric species with occasional
fibrils and that HFIP-based protocols resulted in primarily
oligomeric species with rare or absent fibrils. The HCl-based
protocol yielded primarily fibrillar species. Oligomeric Ab
preparations were used in all studies except as indicated in Fig. 1J.
Quantitation of neuronal survival
p75NTR ligands (LM11A-24 and LM11A-31), NGF or signaling
inhibitors were added concomitantly with Ab. Ab preparations
were added to 6–7 DIV cultures at a final concentration of 5 or
10 mM followed by 72 hours incubation. Following incubation
with Ab neurons were stained with Syto 13 (Molecular Probes),
Hoechst 33258 (Calbiochem); or TUNEL/DAPI, using the
fluorescein-12-dUTP, DeadEndTM Fluorometric TUNEL System
(Promega Madison, WI), and VECTASHIELDH+DAPI (Vector
Labs Burlingame, CA). Stained neurons were visualized under a
fluorescence microscope (Leica DM IRE2) using 520 nm (TU-
NEL, Syto13) or 460 nm (DAPI, Hoechst) filters. Survival of
neurons was determined based on morphological criteria and
Syto-13 (aids in cellular visualization) as assessed by phase contrast
microscopy [47]. A dead or degenerating neuron was defined as
one with a vacuolated cytoplasm, shrunken soma and/or beaded
or retracted neurites. Data are expressed as percent of the total
number of observed neurons that were scored as surviving.
Neuron death was quantified with Hoechst 33258 by counting the
number of cells containing condensed or fragmented nuclei as a
percent of total observed neurons, and also with the TUNEL/
DAPI system, by dividing the number of nuclei exhibiting TUNEL
staining by the total number of nuclei as identified by DAPI. Cell
survival analyses were confirmed by blinded counts.
Quantitation of neuritic dystrophy
21–22 DIV hippocampal neuron cultures were treated with
fresh Neurobasal B27 medium containing Ab at a final
concentration of 5 mM in the presence or absence of LM11A-24
or -31 for 48 hours and then fixed in fresh 4% paraformaldehyde.
Neurites were imaged by immunostaining with MAP-2 monoclo-
nal primary followed by Cy3-conjugated anti-mouse secondary
antibody (Jackson Immunoresearch). MAP2 positive dendrites
were quantitated using the MEASURE COUNT OBJECT
function of MetaMorph 5.0 (Universal Imaging Inc, West Chester,
PA). Only dendrite branches longer than 10 mm were considered
(processes shorter than 10 mm were considered as sprouts).
Dendrites were considered dystrophic when they showed a
persistent pattern of increased tortuosity (multiple abrupt turns).
To more precisely quantitate the degree of neurite curvature, we
modified an established method for assessment of neurite
curvature [31]. In randomly selected fields, neurite courses were
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digitized and approximated by a series of n manually chosen
connected line segments using NIH-Image (Fig. S4). Neurite
analyses were confirmed in a blinded manner. Using a Sigmaplot
macro, the angle of each segment was determined relative to a line
connecting the endpoints of the neurite tracing (a), and, beginning
at one end, successive angles were subtracted from the prior angle
in the chain, and the results averaged to give the ‘mean differential
curvature’ (MDC=S(ai+12ai)/n). This parameter reflects the
degree of curvature over the course of the neurite with an
increasing value indicating increased curvature.
Organotypic hippocampal slice cultures
Organotypic hippocampal slice cultures were prepared using
previously described methods [48] with modification. Briefly,
350 mm thick hippocampal slices were prepared from postnatal 8-
day-old (PND-8) Wistar rats using a tissue chopper and separated
in ice-cold Hank’s balanced salt solution (HBSS) with 33.3 mM
glucose, 4.2 mM NaHPO4, 10 mM MgSO4, 10 mM HEPES,
0.3% BSA and Penicillin-Streptomycin, pH 7.3. Slices were
mounted on Millicell culture inserts and transferred to 6-well
culture plates. Each well contained 1 mL of tissue culture medium
consisting of 50% minimum essential medium, 25% HBSS, 25%
heat inactivated horse serum and supplemented with 33 mM
glucose, 12.5 mM HEPES and penicillin-streptomycin. Prior to
the addition of Ab and small molecules, organotypic cultures were
matured under tissue culture conditions for 11–19 days. Culture
medium was changed three times per week.
Pyramidal neuron death in brain slices was quantitated by
measuring propidium iodide (PI) uptake using a previously
established protocol [48]. In brief, slices were treated with
Ab6LM11A-31 for 24 hours and then with 50 mM N-Methyl-
D-Aspartic acid (NMDA) to induce maximum pyramidal neuron
death in each slice. Cellular damage was assessed by fluorescent
image analysis of propidium iodide uptake (PI; 2 mg/mL),
indicative of significant membrane injury. Before and after
treatment, slices were observed and photographed with an
inverted microscope (Nikon) coupled to a CCD camera, and
mean fluorescent intensity in the CA1-3 regions was determined
using OpenLab 4.04 software. Baseline (i.e. pre-treatment)
fluorescence was subtracted from subsequent measurements and
post-treatment cellular damage was normalized to the total
neuronal density (determined by NMDA-induced PI intensity).
Protein preparation and Western blotting
For assays of AKT, calpain, cdk5 and GSK3b activity, 21–22
DIV hippocampal neurons were incubated for 4 hours in fresh
neurobasal/B27 culture medium containing 5 mM oligomeric Ab
in the presence or absence of LM11A-24, -31 or NGF. Following
incubation, cells were collected and washed in ice-cold PBS and
then lysed in RIPA buffer (20 mM Tris, pH 8.0, 137 mM NaCl,
1% NP-40, 10% glycerol, 1 mM PMSF, 500 mM orthovanadate,
10 mg/ml aprotinin and 1 mg/ml leupeptin). Lysates were
sonicated for 10 seconds, centrifuged at 14,0006g for 10 minutes
at 4uC, and the supernatant was collected. For tau phosphoryla-
tion studies, heat-stable fractions were prepared as described
previously [49]. In brief, cells were collected by scraping cells into
ice-cold TBS and centrifuging at 140006g for 10 min at 4uC. The
supernatant was discarded and the pellet was resuspended in
100 ml MES/NaCl buffer (100 mM MES, 1 M NaCl, 0.5 mM
MgCl2, 1 mM EGTA, 2 mM DTT, 1 mM Na3VO4, 1 mM
benzamidine hydrochloride, 5 mg/ml leupeptin, 2 mg/ml aproti-
nin, 1 mg/ml pepstatin, 0.2 mM PMSF) and immediately heated
to 100uC for 10 min. These were then cooled on ice and
centrifuged at 140006g at 4uC for 25 min. The tau and MAP2c-
enriched supernatant was retained. Phosphorylated CREB (p-
CREB) levels were determined as described previously [21].
Cultured 21–22 DIV hippocampal neurons were treated with
5 mM Ab in Neurobasal medium without B27 supplement or L-
glutamine for 3 hours followed by the addition of 50 mM
glutamine for 15 min in order to promote CREB activation
(phosphorylation). Cells were harvested in 16 modified RIPA
buffer as above with the addition of 80 mM glycerophosphate, and
whole-cell extracts were then prepared. Protein concentrations
were determined using the BCA Protein Assay Reagent (Pierce,
Rockford, IL). Samples were electrophoresed through 4–20%
Tris-HCl Linear Gradient Gels (Bio-Rad, Hercules, CA) and
transferred to PVDF membranes. Western blots were processed
using the ECL Chemiluminescence System (Amersham, Arlington
Heights, IL) and bands were quantitated using densitometry.
Quantitation of c-Jun activation
E16 hippocampal neurons harvested from CF-1 mice were
plated on glass coverslips as described above or on Tissue Tek
chamber slides and at 6–7 DIV were treated with 5–10 mM
oligomeric Ab for 12 hours, then fixed in fresh 4% PFA and
immunostained with phospho-c-Jun specific antibody and DAPI
or Hoechst to label total nuclei [35]. Activation of c-Jun was
quantitated by counting p-c-Jun positive nuclei as a percent of
total neuronal nuclei.
Electrophysiological recordings
Hippocampal slice preparations were performed as described
[21]. Hippocampi were harvested from 3 month old male mice
(C57Bl/6; The Jackson Laboratory). Transverse hippocampal slices
(400 mm in thickness) were cut and maintained in an interface
chamber at 29uC, and perfused with saline solution (124.0 mM
NaCL, 4.4 mM KCL, 1.0 mM Na2HPO4, 25.0 mM NaHCO3,
2.0 mM CaCL2, 2.0 mM MgSO4, and 10 mM glucose) continu-
ously bubbled with 95% O2 and 5% CO2. fEPSPs were recorded
from the CA1 region of the hippocampus by placement of both the
stimulating and the recording electrodes in the CA1 stratum
radiatum. Basal synaptic transmission (BST) was assayed by plotting
of the stimulus voltage (V) against slopes of fEPSP to generate input-
output relations or by plotting of the peak amplitude of the fiber
volley against the slope of the fEPSP to generate input-output
relations. LTP was induced using theta-burst stimulation (4 pulses at
100 Hz, with the bursts repeated at 5 Hz, and each tetanus
including 3 10-burst trains separated by 15 seconds). LM11A-31
(100 nM) (dissolved in H2O) or vehicle (H2O) was added to the bath
solution for 20 minutes prior to the induction of LTP in studies in
which Ab (200 nM) was added to slice preparations. Oligomeric
Ab(1-42) was prepared using HFIP [45].
Statistical analysis
Statistical analyses applied ANOVA with Dunnett’s correction
except for the following: in Fig. 2 and Fig. 5B ANOVA with
Tukey-Kramer correction was applied; and in Fig. 6 two-way
ANOVA was applied. For all bar graphs, mean6SE is shown. For
all figures: *p,0.05, **p,0.01, ***p,0.001.
Supporting Information
Figure S1 Small molecule structures. Structures of LM11A-31,
LM11A-24 and LM11A-36 are shown. LM11A-36 is identical to
LM11A-24 except that it contains two additional methyl groups
and is inactive. These compound structures were published
previously [17].
Found at: doi:10.1371/journal.pone.0003604.s001 (0.10 MB TIF)
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Figure S2 AFM imaging of Ab preparations. Images are
representative ,161 mm scans with z-height 10 nm. Incubation
Ab(1-42) peptide in NaOH (A) or NH4OH (B) demonstrates
primarily oligomeric structures with occasional fibrillar structures.
(C) Ab preparation derived from HFIP-processing of Ab followed
by PBS incubation demonstrates oligomeric structure with no
observed fibrils. (D) Ab fibril preparation derived from HFIP-
processing of Ab followed by HCl incubation demonstrates
primarily fibril-like structures.
Found at: doi:10.1371/journal.pone.0003604.s002 (6.83 MB TIF)
Figure S3 LM11A-24 and -31 inhibit Ab-induced death of
hippocampal neurons as assayed by Hoechst staining. 6–7 DIV
hippocampal neurons were treated with (A) culture medium (CM)
alone; (B) 10 mM Ab; (C) 10 mM Ab with 100 nM LM11A-24; (D)
10 mM Ab with 100 nM LM11A-31 for 72 hours, then stained
with Hoechst 33258, fixed and photographed with fluorescence
microscopy. Many neurons exposed to Ab exhibited nuclear
condensation and fragmentation, indicative of death (arrows in B),
whereas the majority of neurons co-treated with Ab and LM11A-
24 or -31 had diffuse, even nuclei, similar to the control condition.
(E) Treatment with Ab resulted in an approximately 4-fold
increase in neuronal death. Co-treatment with 100 nM LM11A-
24 or -31, but not NGF, prevented Ab-induced death (n = 18–58
fields derived from 3–6 separate experiments). Each condition was
compared to Ab alone.
Found at: doi:10.1371/journal.pone.0003604.s003 (0.65 MB TIF)
Figure S4 Illustration of neurite curvature quantitation. As
described in Methods, neurites were traced manually in the form
of a series of short vectors (small arrows along neurites) to
determine the angles (ai, ai+1…) created by each vector and a line
connecting the origin and termination of the measured segment.
The differences between successive angles (e.g. ai+1-ai) were
averaged to generate a mean differential curvature (MDC) score.
The upper panel demonstrates a neurite in culture medium alone
(CM) with a mean differential curvature of 10.7 and the lower
panel demonstrates a neurite exposed to Ab with a mean
differential curvature of 29.3.
Found at: doi:10.1371/journal.pone.0003604.s004 (1.92 MB TIF)
Table S1 Cerep receptor screen. Compound LM11A-31 was
submitted to Cerep Inc. (Seattle, WA) and applied to the
ExpresSProfile receptor screen. Values shown indicate the percent
by which binding of a control ligand is inhibited by the test
compound. Inhibition of binding by ,20% is interpreted as no
significant binding detected.
Found at: doi:10.1371/journal.pone.0003604.s005 (0.10 MB
DOC)
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